Equillium Inc

EQ

Company Profile

  • Business description

    Equillium Inc is a clinical-stage biotechnology company engaged in developing novel therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. The company intends to commercialize its product candidates either independently or through partnerships, or otherwise monetize its pipeline through strategic transactions. Itolizumab (EQ001), a clinical-stage product candidate, is an anti-CD6 immune-modifying monoclonal antibody, or mAb, that selectively targets the CD6-ALCAM signaling pathway to downregulate pathogenic T effector cells while preserving T regulatory cells critical for maintaining a balanced immune response. The company's other clinical-stage and pre-clinical-stage candidates include EQ101 and EQ302.

  • Contact

    2223 Avenida De La Playa
    Suite 105
    La JollaCA92037
    USA

    T: +1 858 240-1200

    E: [email protected]

    https://www.equilliumbio.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    35

Stocks News & Analysis

stocks

This might be the best core stock bargain in the US market today

Patient investors should consider building a position in this wide-moat stock while it’s seriously undervalued.
stocks

Data center demand drives strong earnings outlook for SGM

Sims guides huge earnings upgrade as data center metals demand spikes.
stocks

Chart of the Week: AI proving a threat to company moats

The latest insights on AI from our equity research team.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,637.6025.50-0.29%
CAC 407,807.87162.01-2.03%
DAX 4022,839.56662.69-2.82%
Dow JONES (US)46,021.43203.72-0.44%
FTSE 10010,063.50241.79-2.35%
HKSE25,340.43160.15-0.63%
NASDAQ22,090.6961.73-0.28%
Nikkei 22553,372.531,866.87-3.38%
NZX 50 Index12,989.9961.62-0.47%
S&P 5006,606.4918.21-0.27%
S&P/ASX 2008,443.7028.60-0.34%
SSE Composite Index4,013.166.610.16%

Market Movers